NFL's Eric Berry has Hodgkin's Lymphoma

Results are back for 25 year old Kansas City Chiefs safety Eric Berry—as suspected, Berry has lymphoma, specifically, Hodgkin's lymphoma.

“This is a diagnosis that is very treatable and potentially curable with standard chemotherapy approaches,” said Christopher R. Flowers, director of the Winship Cancer Institute lymphoma program at Emory University in Atlanta. “The goal of Mr. Berry’s treatment is to cure his lymphoma and we are beginning that treatment now.”

Because Berry is from Fairburn, GA, he is being treated at Emory so that he can be nearer to his family for support.

“My family and I are very grateful for the amount of support we have received over the last couple of weeks,” said Berry in a statement released Monday. “I can’t tell you enough how much I appreciate all the words of encouragement, the blessings and well wishes. I want to thank the Emory University School of Medicine, along with Dr. Flowers and his team, for all of their hard work and effort in diagnosing and creating a plan for me to battle this thing. I will embrace this process and attack it the same way I do everything else in life. God has more than prepared me for it. For everyone sharing similar struggles, I’m praying for you and keep fighting!”

Berry initially complained about pain in his chest back on November 20. Initial testing showed a mass in his chest.

Source: The Kansas City Star

Photo of Eric Berry by Jeffrey Beall. Licensed under CC BY-SA 3.0 via Wikimedia Commons

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap